Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders

MLA

Andreas A. Argyriou, et al. Beyond Chronic Migraine: A Systematic Review and Expert Opinion on the off-Label Use of Botulinum Neurotoxin Type-A in Other Primary Headache Disorders. Jan. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....aa1103ce2544f0eb91f4bbf5ef9c9844&authtype=sso&custid=ns315887.

APA

Andreas A. Argyriou, Michail Vikelis, Dimos-Dimitrios Mitsikostas, Stefano Tamburin, & Elisa Mantovani. (2021). Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders.

Chicago

Andreas A. Argyriou, Michail Vikelis, Dimos-Dimitrios Mitsikostas, Stefano Tamburin, and Elisa Mantovani. 2021. “Beyond Chronic Migraine: A Systematic Review and Expert Opinion on the off-Label Use of Botulinum Neurotoxin Type-A in Other Primary Headache Disorders,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....aa1103ce2544f0eb91f4bbf5ef9c9844&authtype=sso&custid=ns315887.